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As health care spending continues to rise (World Health
Organization, 2006), resource allocation decisions will
need to be based increasingly on information about preva-
lence and severity of disorders and cost-effectiveness of
interventions. This will require disorder-specific informa-
tion to be obtained not only about prevalence, but also
about disability (Katschnig et al., 1997; Murray & Lopez,
1996). Despite the fact that many studies in developed
countries have estimated the effects of specific disorders on
disability (Berto et al., 2000; Maetzel & Li, 2002; Reed et
al., 2004), comparative studies are rare (Druss et al., 2008;
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SUMMARY. Aims – The paper reviews recent findings from the WHO World Mental Health (WMH) surveys on the global burden
of mental disorders. Methods – The WMH surveys are representative community surveys in 28 countries throughout the world aimed
at providing information to mental health policy makers about the prevalence, distribution, burden, and unmet need for treatment of com-
mon mental disorders. Results – The first 17 WMH surveys show that mental disorders are commonly occurring in all participating coun-
tries. The inter-quartile range (IQR: 25th-75th percentiles) of lifetime DSM-IV disorder prevalence estimates (combining anxiety, mood,
externalizing, and substance use disorders) is 18.1-36.1%. The IQR of 12-month prevalence estimates is 9.8-19.1%. Prevalence estimates
of 12-month Serious Mental Illness (SMI) are 4-6.8% in half the countries, 2.3-3.6% in one-fourth, and 0.8-1.9% in one-fourth. Many
mental disorders begin in childhood-adolescence and have significant adverse effects on subsequent role transitions in the WMH data.
Adult mental disorders are found to be associated with such high role impairment in the WMH data that available clinical interventions
could have positive cost-effectiveness ratios. Conclusions – Mental disorders are commonly occurring and often seriously impairing in
many countries throughout the world. Expansion of treatment could be cost-effective from both employer and societal perspectives.
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Merikangas et al., 2007). Recognizing the importance of
this information, one of the main aims of the WHO World
Mental Health (WMH) Surveys is to produce data on the
prevalence and severity of mental disorders in each partic-
ipating WMH country. Although this is still a work in
progress, enough useful information has been produced on
overall prevalence and severity of mental disorders in the
WMH surveys to warrant a review of this evidence.
THE WHO WORLD MENTAL HEALTH (WMH)
SURVEY INITIATIVE
The WMH Survey Initiative is an initiative of the
World Health Organization (WHO) designed to help
countries throughout the world carry out and analyze epi-
demiological surveys of the prevalence and correlates of
mental disorders. A key aim of the WMH surveys is to
help countries that would not otherwise have the exper-
tise or infrastructure to implement high quality commu-
nity epidemiological surveys by providing centralized
instrument development, training, and data analysis
(www.hcp.med.harvard.edu/wmh). Twenty-eight coun-
tries have so far completed WMH surveys. The vast
majority of these surveys are nationally representative,
although a few are representative of only a single region
(e.g., the San Paolo metropolitan area in Brazil) or
regions (e.g., six metropolitan areas in Japan).
All WMH surveys use the same diagnostic interview,
the WHO Composite International Diagnostic Interview
(CIDI) (Kessler & Üstün, 2004). The CIDI is a state-of-
the-art fully-structured research diagnostic interview
designed to be used by trained lay interviewers who do not
have any clinical experience. Consistent training materi-
als, training programs, and quality control monitoring pro-
cedures are used in all WMH surveys to guarantee compa-
rability across surveys. Consistent WHO translation, back-
translation, and harmonization procedures for the survey
and the training materials are also used across countries.
The use of a fully-structured interview was critical to
the success of the WMH, as many participating countries
do not have the critical mass of trained mental health pro-
fessions needed to implement a large-scale clinical sur-
vey. However, the WMH collaborators are encouraged to
carry out blinded clinician re-interviews with a probabili-
ty sub-sample of WMH respondents in order to confirm
that the diagnoses generated by the CIDI are consisted
with independent clinical diagnoses generated by cultur-
ally competent clinicians. Methodological studies of these
clinical reappraisal interviews have documented good
concordance with CIDI diagnoses (Haro et al., 2006).
The CIDI was designed to go well beyond the mere
assessment of mental disorders to include a wide range of
measures about a number of correlates. For the purposes
of this report, two of these extensions need to be noted.
One is that the CIDI includes a disorder-specific measure
of role impairment that is administered in exactly the
same fashion for each mental disorder assessed in the sur-
veys and for each of the physical disorders assessed for
comparison purposes in the surveys. This measure is
known as the Sheehan Disability Scales (SDS). The SDS
is a widely used self-report measure of condition-specif-
ic role impairment that consists of four questions, each
asking the respondent to rate on a 0-10 scale the extent to
which a particular disorder “interfered with” activities in
one of four role domains during the month in the past
year when the disorder was most severe. The four
domains include:
i) “your home management, like cleaning, shopping,
and taking care of the (house/apartment)” (home);
ii) “your ability to work” (work);
iii) “your social life” (social); and
iv) “your ability to form and maintain close relationships
with other people” (close relationships). The 0-10
response options were presented in a visual analogue
format with labels for the response options None (0),
Mild (1-3), Moderate (4-6), Severe (7-9), and Very
Severe (10). A global SDS disability score was also
created by assigning each respondent the highest SDS
domain score reported across the four domains.
Previous methodological studies have documented
good internal consistency reliability across the SDS
domains (Hambrick et al., 2004; Leon et al., 1997), a
result that we replicated in the WMH data by finding
Cronbach’s alpha (a measure of internal consistency reli-
ability) in the range .82-.92 across countries. Importantly,
reliability was high both in developed countries (median
.86; inter-quartile range .84-.88) and developing countries
(median .90; inter-quartile range .88-.90). Previous
methodological studies have also documented good dis-
crimination between role functioning of cases and con-
trols based on SDS scores in studies of social phobia
(Hambrick et al., 2004), PTSD (Connor & Davidson,
2001), panic disorder (Leon et al., 1997), and substance
abuse (Pallanti et al., 2006). Similar results were found in
the WMH surveys in responses to a question asked after
the SDS about “How many days out of 365 in the past
year were you totally unable to work or carry out you nor-
mal activities because of (the illness)?” If the SDS mea-
sures genuine disability, we would expect correlations of
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SDS scores to be significant and comparable for physical
and mental disorders with this relatively objective mea-
sure of disability. That is, in fact, what we found. In devel-
oped countries, the multiple correlations of the four SDS
domain scores predicting days out of role were .55 for
mental disorders and .50 for physical disorders, while the
comparable correlations in less developed countries were
.39 for mental disorders and .36 for physical disorders.
Second, the CIDI assesses disorder severity. This is
important in light of the finding in previous epidemiolog-
ical surveys that quite a high proportion of the general
population in many countries meets criteria for a DSM or
ICD mental disorder (Somers et al., 2006; Waraich et al.,
2004; Wittchen & Jacobi, 2005). Faced with this high
prevalence, mental health policy planning efforts need to
consider disorder severity for treatment planning purpos-
es, as the simple presence of a diagnosis may not indicate
the level of need for services. All 12-month cases were
consequently classified as either serious, moderate, or
mild. Serious disorders were defined as: non-affective
psychosis, bipolar I disorder or substance dependence
with a physiological dependence syndrome; making a sui-
cide attempt in conjunction with any other disorder;
reporting severe role impairment due to a mental disorder
in at least two areas of functioning measured by the SDS
or having overall functional impairment from any disorder
consistent with a Global Assessment of Functioning
(GAF) (Endicott et al., 1976) score of 50 or less.
Disorders not classified as serious were classified as mod-
erate if the respondent had: substance dependence without
a physiological dependence syndrome; or at least moder-
ate interference in the disorder-specific scale of role
impairment. All other disorders were classified as mild.
DISORDER PREVALENCE ESTIMATES
IN THE WMH SURVEYS
The WMH surveys that have been completed so far
show clearly that mental disorders are quite common in
all the countries studied. The inter-quartile range (IQR;
25th-75th percentiles across countries) of lifetime preva-
lence estimates of any DSM-IV disorder assessed in the
CIDI across these surveys is 18.1-36.1% in this set of sur-
veys. (Table I) A lifetime DSM/CIDI diagnosis was
found among more than one--third of respondents in five
countries (Colombia, France, New Zealand, Ukraine,
United States), more than one--fourth in six (Belgium,
Germany, Lebanon, Mexico, Netherlands, South Africa),
and more than one-sixth in four (Israel, Italy, Japan,
Spain). The remaining two countries, China (13.2%) and
Nigeria (12.0%), had considerably lower prevalence esti-
mates that are likely to be downwardly biased (Gureje et
al., 2006; Shen et al., 2006). Prevalence estimates for
other developing countries were all above the lower
bound of the IQR. When coupled with the fact that our
clinical reappraisal studies showed prevalence estimates
in developed countries to be accurate and with the possi-
bility that prevalence estimates in less developed coun-
tries are under-estimated, these results argue persuasive-
ly that mental disorders have great public health impor-
tance throughout the world.
As noted above, a number of recent literature reviews
have presented detailed comparative data on the preva-
lence estimates for individual mental disorders and class-
es of disorder across all recently published community
epidemiological surveys (Somers et al., 2006; Waraich et
al., 2004; Wittchen & Jacobi, 2005). Several consistent
patterns are found in these reviews that are replicated in
the WMH surveys. One is that anxiety disorders are con-
sistently found to be the most prevalent class of mental
disorders in the general population, with estimated life-
time prevalence of any anxiety disorder averaging
approximately 16% and 12-month prevalence averaging
approximately 11% across surveys. There is wide varia-
tion around these averages, though, with prevalence esti-
mates generally higher in Western developed countries
than in developing countries. This same pattern can be
seen in the first set of WMH surveys to be completed,
where the median lifetime prevalence estimate of any
anxiety disorder is somewhat higher for anxiety disorders
than in the larger literature – 14.3%, with an IQR of 9.9-
16.7%. The 12-month prevalence estimates, in compari-
son, average 8.3% for any anxiety disorder with an IQR
of 6.5-12.1. (Table II)
Mood disorders are generally found to be the next
most prevalent class of mental disorders in community
epidemiological surveys, with lifetime prevalence esti-
mates of any mood disorder averaging approximately
12% and 12-month prevalence estimates averaging
approximately 6%. Again, prevalence estimates are gen-
erally higher in Western developed countries than in
developing countries. The median WMH lifetime preva-
lence estimate for any mood disorder is somewhat lower
than the average in the literature: 10.6% with an IQR of
7.6-17.9%. The 12-month prevalence estimates for any
mood disorder in the WMH surveys average 5.1%, with
an IQR of 3.4-6.8.
The other two commonly occurring classes of disor-
ders assessed in the WMH surveys are externalizing dis-
orders (attention-deficit/hyperactivity disorder, opposi-
tional-defiant disorder, conduct disorder, and intermittent
Epidemiologia e Psichiatria Sociale, 18, 1, 2009
25
The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1121189X00001421
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 15:54:41, subject to the Cambridge Core terms of use, available at
explosive disorder) and substance use disorders (alcohol
and illicit drug abuse and dependence). Impulse-control
disorders are the less prevalent of these two in terms of
lifetime prevalence in most of the WMH countries that
included a relatively full assessment of these disorders
(0.3-25.0%, IQR: 3.1-5.7%). Substance use disorders are
generally less prevalent elsewhere (1.3-15.0%, IQR: 4.8-
9.6). The Western European countries did not assess illic-
it drug abuse or dependence, though, leading to artificial-
ly low lifetime prevalence estimates (1.3-8.9%) com-
pared to other countries (2.2-15.0%). Substance depen-
dence was also assessed only in the presence of abuse,
possibly further reducing estimated prevalence (Hasin &
Grant, 2004). The same general pattern holds for 12-
month prevalence, where substance disorders (0.2-6.4%;
IQR: 1.2-2.8%) and impulse-control disorders (0.1-
10.5%; IQR: 0.6-2.6%) are consistently less prevalent
than anxiety or mood disorders.
Focusing on individual disorders, specific phobia is
generally found to be the most prevalent mental disorder
in community epidemiological surveys, with lifetime
prevalence estimates usually in the 6-12% range and 12-
month prevalence estimates in the 4-8% range
(Silverman & Moreno, 2005). Major depressive disorder
(MDD) is generally found to be the next most prevalent
disorder, with lifetime prevalence estimates usually in the
4-10% range and 12-month prevalence estimates in the 3-
6% range (Judd & Akiskal, 2000). Social phobia is gen-
erally found to be the next most prevalent disorder, with
prevalence estimates sometimes approaching those of
MDD (Furmark, 2002). The WMH estimates are general-
ly quite consistent with these more general patterns.
R. C. Kessler et al.
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Table I – Lifetime prevalence estimates of DSM-IV / CIDI disorders in the WMH surveys1, 2
Any anxiety disorder Any mood disorder Any externalizing disorder Any substance disorder Any disorder
% (se) % (se) % (se) % (se) % (se)
I. WHO Region: Pan American Health Organization (PAHO)
Colombia 25.3 (1.4) 14.6 (0.7) 9.6 (0.8) 9.6 (0.6) 39.1 (1.3)
Mexico 14.3 (0.9) 9.2 (0.5) 5.7 (0.6)6 7.8 (0.5) 26.1 (1.4)
United States 31.0 (1.0) 21.4 (0.6) 25.0 (1.1) 14.6 (0.6) 47.4 (1.1)
II. WHO Region: African Regional Office (AFRO)
Nigeria 6.5 (0.9) 3.3 (0.3) 0.3 (0.1)7, 9 3.7 (0.4) 12.0 (1.0)
South Africa 15.8 (0.8)3, 4 9.8 (0.7)5 –– ––6, 7, 8, 9 13.3 (0.9) 30.3 (1.1)
III. WHO Region: Eastern Mediterranean Regional Office (EMRO)
Lebanon 16.7 (1.6) 12.6 (0.9) 4.4 (0.9)9 2.2 (0.8) 25.8 (1.9)
IV. WHO Region: European Regional Office (EURO)
Belgium 13.1 (1.9) 14.1 (1.0)5 5.2 (1.4)6 8.3 (0.9)10 29.1 (2.3)
France 22.3 (1.4) 21.0 (1.1)5 7.6 (1.3)6 7.1 (0.5)10 37.9 (1.7)
Germany 14.6 (1.5) 9.9 (0.6)5 3.1 (0.8)6 6.5 (0.6)10 25.2 (1.9)
Israel 5.2 (0.3)3, 4 10.7 (0.5) –– ––6, 7, 8, 9 5.3 (0.3) 17.6 (0.6)
Italy 11.0 (0.9) 9.9 (0.5)5 1.7 (0.4)6 1.3 (0.2)10 18.1 (1.1)
The Netherlands 15.9 (1.1) 17.9 (1.0)5 4.7 (1.1)6 8.9 (0.9)10 31.7 (2.0)
Spain 9.9 (1.1) 10.6 (0.5)5 2.3 (0.8)6 3.6 (0.4)10 19.4 (1.4)
Ukraine 10.9 (0.8)3, 4 15.8 (0.8)5 8.7 (1.1)7, 9 15.0 (1.3) 36.1 (1.5)
V. WHO Region: Western Pacific Regional Office (WPRO)
PRC11 4.8 (0.7) 3.6 (0.4) 4.3 (0.9)7, 9 4.9 (0.7) 13.2 (1.3)
Japan 6.9 (0.6)3 7.6 (0.5) 2.8 (1.0)7, 8, 9 4.8 (0.5) 18.0 (1.1)
New Zealand 24.6 (0.7)3 20.4 (0.5) –– ––6, 7, 8, 9 12.4 (0.4) 39.3 (0.9)
1Anxiety disorders include Agoraphobia, Adult Separation Anxiety Disorder, Generalized Anxiety Disorder, Panic Disorder, Post-Traumatic Stress
Disorder, Social Phobia, and Specific Phobia. Mood disorders include Bipolar Disorders, Dysthymia, and Major Depressive Dsorder. Impulse-con-
trol disorders include Intermittent Explosive Disorder, and reported persistence in the past 12 months of symptoms of three child-adolescent disor-
ders (Attention-Deficit Hyperactivity Disorder, Conduct Disorder, and Oppositional-Defiant Disorder). Substance disorders include Alcohol or Drug
Abuse with or without Dependence. In the case of substance dependence, respondents who met full criteria at some time in their life and who con-
tinue to have any symptoms are considered to have 12-month dependence even if they currently do not meet full criteria for the disorder. Organic
exclusions were made as specified in the Diagnostic and Statistical Manual of Mental Health Disorders, Fourth Edition.
2Impulse disorders restricted to age < 39 (China, Ukraine, Nigeria) or to age < 44 (all other countries).
3Adult Separation Anxiety Disorder was not assessed.
4Specific Phobia was not assessed.
5Bipolar Disorders were not assessed.
6Intermittent Explosive Disorder was not assessed.
7Attention-Deficit Hyperactivity Disorder was not assessed.
8Conduct Disorder was not assessed.
9Oppositional-Defiant Disorder was not assessed.
10Only alcohol abuse with or without dependence were assessed. No assessment was made of other Drug Abuse with or without dependence.
11People’s Republic of China.
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It is important to note that these relatively high preva-
lence estimates are, if anything, conservative, as contro-
versy exists regarding the possibility that the current
diagnostic criteria in the DSM and ICD systems are over-
ly conservative. For example, in the case of both post-
traumatic stress disorder (PTSD) (Mylle & Maes, 2004)
and generalized anxiety disorder (GAD) (Ruscio et al.,
2007), good evidence exists from epidemiological sur-
veys that one or more diagnostic criteria define a much
more restrictive set of cases than the other criteria, call-
ing into question the wisdom of including the restrictive
criterion. A related issue is that considerable evidence
exists for the existence of clinically significant sub-
threshold manifestations of many mental disorders that
are much more prevalent than the disorders themselves
(Brown & Barlow, 2005). For example, even though
OCD is almost always estimated to be fairly rare in gen-
eral population surveys, sub-threshold manifestations of
OCD, some of them appearing to be clinically significant,
are fairly common (Matsunaga & Seedat, 2007). The
same is true for bipolar spectrum disorder, where even
though the lifetime prevalence of BP-I is estimated to be
only about 0.8-1.5%, the combined prevalence of BP-I,
BP-II, and clinically significant sub-threshold BPD is
likely in the range 4-6% (Skeppar & Adolfsson, 2006).
However, as community epidemiological surveys have
for the most part not explored these sub-threshold mani-
festations systematically, we do not currently have good
estimates of the proportion of the population that would
meet criteria for one or more anxiety and mood spectrum
disorders.
DISORDER SEVERITY
While many previous epidemiological surveys esti-
mated disorder prevalence, the WMH surveys are the first
ones to generate systematic estimates of disorder severi-
Epidemiologia e Psichiatria Sociale, 18, 1, 2009
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Table II – 12-month prevalence estimates of DSM-IV/CIDI disorders in the WMH surveys1, 2
Any anxiety disorder Any mood disorder Any externalizing disorder* Any substance disorder Any disorder
% (se) % (se) % (se) % (se) % (se)
I. WHO Region: Pan American Health Organization (PAHO)
Colombia 14.4 (1.0) 7.0 (0.5) 4.4 (0.4) 2.8 (0.4) 21.0 (1.0)
Mexico 8.4 (0.6) 4.7 (0.3) 1.6 (0.3)6 2.3 (0.3) 13.4 (0.9)
United States 19.0 (0.7) 9.7 (0.4) 10.5 (0.7) 3.8 (0.4) 27.0 (0.9)
II. WHO Region: African Regional Office (AFRO)
Nigeria 4.2 (0.5) 1.1 (0.2) 0.1 (0.0)7, 9 0.9 (0.2) 6.0 (0.6)
South Africa 8.2 (0.6)3, 4 4.9 (0.4)5 1.9 (0.3)7, 8, 9 5.8 (0.5) 16.7 (1.0)
III. WHO Region: Eastern Mediterranean Regional Office (EMRO)
Lebanon 12.2 (1.2) 6.8 (0.7) 2.6 (0.7)9 1.3 (0.8) 17.9 (1.7)
IV. WHO Region: European Regional Office (EURO)
Belgium 8.4 (1.4) 5.4 (0.5)5 1.7 (1.0)6 1.8 (0.4)10 13.2 (1.5)
France 13.7 (1.1) 6.5 (0.6)5 2.4 (0.6)6 1.3 (0.3)10 18.9 (1.4)
Germany 8.3 (1.1) 3.3 (0.3)5 0.6 (0.3)6 1.2 (0.2)10 11.0 (1.3)
Israel 3.6 (0.3)3, 4 6.4 (0.4) –– ––6, 7, 8, 9 1.3 (0.2) 10.0 (0.5)
Italy 6.5 (0.6) 3.4 (0.3)5 0.4 (0.2)6 0.2 (0.1)10 8.8 (0.7)
The Netherlands 8.9 (1.0) 5.1 (0.5)5 1.9 (0.7)6 1.9 (0.3)10 13.6 (1.0)
Spain 6.6 (0.9) 4.4 (0.3)5 0.5 (0.2)6 0.7 (0.2)10 9.7 (0.8)
Ukraine 6.8 (0.7)3, 4 9.0 (0.6)5 5.7 (1.0)7, 9 6.4 (0.8) 21.4 (1.3)
V. WHO Region: Western Pacific Regional Office (WPRO)
PRC11 3.0 (0.5) 1.9 (0.3) 3.1 (0.7)7, 9 1.6 (0.4) 7.1 (0.9)
Japan 4.2 (0.6)3 2.5 (0.4) 0.2 (0.1)7, 8, 9 1.2 (0.4) 7.4 (0.9)
New Zeland 15.0 (0.5)3 8.0 (0.4) –– ––6, 7, 8, 9 3.5 (0.2) 20.7 (0.6)
1See the notes Table 1 for a listing of the disorders included in each entry
2Impulse disorders restricted to age < 39 (China, Ukraine, Nigeria) or to age < 44 (all other countries).
3Adult Separation Anxiety Disorder was not assessed.
4Specific Phobia was not assessed.
5Bipolar Disorders were not assessed.
6Intermittent Explosive Disorder was not assessed.
7Attention-Deficit Hyperactivity Disorder was not assessed.
8Conduct Disorder was not assessed.
9Oppositional-Defiant Disorder was not assessed.
10Only alcohol abuse with or without dependence were assessed. No assessment was made of other Drug Abuse with or without dependence.
11People’s Republic of China.
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The finding of a positive association between estimat-
ed prevalence and severity across countries is potentially
important because it speaks to an issue that has been
raised in the methodological literature regarding the pos-
sibility of biased prevalence estimates. Two separate
research groups found an opposite sort of effect. A report
comparing results from the Korean Epidemiologic
Catchment Area (KECA) Study (Chang et al., 2008) with
results from a parallel survey in the US argued that the
lower estimated prevalence of major depression in the
KECA than the US survey was due, at least in part, to a
higher threshold for reporting depression among people
in the Korean population than in the US. In support of
this assertion, the investigators showed that Koreans
diagnosed as depressed with an earlier version of the
CIDI, which was the diagnostic instrument used in the
KECA survey, had considerably higher levels of role
impairment than respondents diagnosed as depressed
using the same instrument in the US.
A similar finding was reported in a methodological
study carried out as part of the WHO Collaborative Study
on Psychological Problems in General Health Care (PPG)
(Üstün & Sartorius, 1995). In that study, nearly 26,000
primary care patients in 14 countries were assessed using
an earlier version of the CIDI that included an evaluation
of current symptoms of depression. As in the WMH sur-
veys, substantial cross-national variation was found in
the prevalence of major depression. However, the inves-
tigators found that the average amount of impairment
associated with depression across countries was inverse-
ty. The proportions of 12-month DSM disorders classi-
fied either serious (12.8-36.8%; IQR: 18.5-25.7%) or
moderate (12.5-47.6%; IQR: 33.9-42.6%) in the first set
of completed WMH surveys, using the definitions of
those terms described above, are generally smaller than
the proportions with a mild disorder. (Table III) The
severity distribution among cases varies significantly
across countries («232 = 153.5, p < .001), with severity
not strongly related either to region or to development
status. The unconditional 12-month prevalence estimate
of serious mental illness (SMI) in the WMH surveys is in
the range 4.0-6.8% for half the surveys, 2.3-3.6% for
another quarter, and 0.8-1.9% for the final quarter. There
are substantial positive associations, though, between
overall prevalence of any disorder and both the propor-
tion of cases classified serious (Pearson r = .46, p < .001)
and the proportion of cases classified either serious or
moderate (Pearson r = .77, p < .001).
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Table III – Prevalence of 12-month DSM-IV/CIDI disorders by severity in the WMH surveys1
Serious Moderate Mild
% (se) % (se) % (se)
I. WHO Region: Pan American Health Organization (PAHO)
Colombia 23.1 (2.1) 41.0 (2.6) 35.9 (2.1)
Mexico 25.7 (2.4)6 33.9 (2.2) 40.5 (2.6)
United States 25.2 (1.4) 39.2 (1.2) 35.7 (1.4)
II. WHO Region: African Regional Office (AFRO)
Nigeria 12.8 (3.8) 12.5 (2.6) 74.7 (4.2)
South Africa 25.7 (1.8) 31.5 (2.2) 42.8 (2.2)
III. WHO Region: Eastern Mediterranean Regional Office (EMRO)
Lebanon 22.4 (3.1) 42.6 (4.7) 35.0 (5.5)
IV. WHO Region: European Regional Office (EURO)
Belgium 31.8 (4.2) 37.8 (3.3) 30.4 (4.8)
France 18.5 (2.5) 42.7 (3.0) 38.8 (3.6)
Germany 21.3 (2.5) 42.6 (4.6) 36.1 (4.3)
Israel 36.8 (2.4) 35.2 (2.3) 28.0 (2.1)
Italy 15.9 (2.7) 47.6 (3.8) 36.5 (3.9)
The Netherlands 30.7 (3.4) 31.0 (3.7) 38.3 (4.6)
Spain 19.3 (2.4) 42.3 (4.0) 38.4 (4.7)
Ukraine 22.9 (1.8) 39.4 (2.9) 37.7 (3.5)
V. WHO Region: Western Pacific Regional Office (WPRO)
PRC11 13.8 (3.7) 32.2 (4.9) 54.0 (4.6)
Japan 13.2 (3.1) 45.5 (5.3) 41.3 (4.6)
New Zeland 25.3 (1.0) 40.8 (1.4) 33.9 (1.2)
1See the text for a description of the coding rules used to define the severity levels.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1121189X00001421
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 15:54:41, subject to the Cambridge Core terms of use, available at
Epidemiologia e Psichiatria Sociale, 18, 1, 2009
29
The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys
ly proportional to the estimated prevalence of depression
in those countries (Chang et al., 2008; Simon et al.,
2002). This result is consistent with the possibility that
the substantial differences in estimated prevalence of
depression in the PPG study might be due, at least in part,
to cross-national differences in diagnostic thresholds.
However, as shown in Table III, we do not replicate this
result in the WMH surveys. The countries with the low-
est prevalence estimates of the DSM-IV disorders
assessed in the WMH surveys also have the lowest
reported levels of impairment associated with those dis-
orders.
Table IV – Association between severity of 12-month DSM-IV/CIDI disorders and days out of role in the WMH surveys.
Serious Moderate Mild
Mean (se) Mean (se) Mean (se) Wald F1 (p-value)
I. WHO Region: Pan American Health Organization (PAHO)
Colombia 53.0 (8.9) 33.7 (6.7) 15.6 (3.0) 10.8* (<.001)
Mexico 42.8 (6.9) 26.3 (5.3) 11.7 (2.7) 11.7* (<.001)
United States 135.9 (6.9) 65.3 (4.6) 35.7 (2.7) 126.1* (<.001)
II. WHO Region: African Regional Office (AFRO)
Nigeria 56.7 (22.3) 51.5 (18.8) 25.9 (7.4) 1.6 (.20)
South Africa 73.1 (9.7) 49.3 (6.5) 32.5 (4.8) 9.1* (<.001)
III. WHO Region: Eastern Mediterranean Regional Office (EMRO)
Lebanon 81.4 (10.6) 42.0 (9.5) 13.6 (5.4) 14.4* (<.001)
IV. WHO Region: European Regional Office (EURO)
Belgium 96.1 (26.0) 59.9 (11.6) 42.5 (9.6) 3.7* (.025)
France 105.7 (14.3) 71.8 (16.5) 67.6 (17.3) 2.7 (.07)
Germany 77.8 (18.1) 33.2 (8.2) 45.7 (12.1) 2.2 (.12)
Israel 184.6 (12.5) 109.4 (10.1) 44.6 (9.1) 41.8* (<.001)
Italy 178.5 (25.6) 55.6 (10.9) 41.7 (11.2) 11.7* (<.001)
The Netherlands 140.7 (19.9) 87.1 (17.1) 68.9 (22.7) 4.0* (.018)
Spain 131.5 (15.8) 56.6 (10.0) 57.4 (22.0) 8.1* (<.001)
Ukraine 142.5 (14.5) 103.2 (9.2) 51.6 (9.9) 13.9* (<.001)
V. WHO Region: Western Pacific Regional Office (WPRO)
PRC11 48.7 (18.4) 21.1 (5.2) 21.3 (7.2) 1.5 (.23)
Japan 51.0 (17.3) 39.3 (10.6) 22.5 (6.4) 3.7* (.024)
New Zeland 98.1 (5.9) 54.6 (3.4) 36.4 (3.6) 40.7* (<.001)
1No demographic controls were used.
*Significant association between severity and days out of role at the .05 level.
It is important to mention here a point briefly touched
on earlier: that the severity classification used in the
WMH surveys was validated by documenting a consis-
tently monotonic association between reported disorder
severity and mean number of days out of role associated
with the disorders. This association is statistically signifi-
cant in all but four surveys (Table IV). Respondents with
serious disorders in most surveys reported at least 40 days
in the past year when they were totally unable to carry out
usual activities because of these disorders (IQR: 56.7-
135.9 days). The mean days out of role for mild disorders,
in comparison, is in the range 11.7-68.9 days, while the
mean for moderate disorders is intermediate between
these extremes (21.1-109.4 days; IQR: 39.3-65.3 days).
When we compare between-country differences in these
means with between-country differences in prevalence,
using the same logic as in the previous paragraph, we once
again find a positive association between prevalence and
this indicator of role impairment. For example, in the three
countries with the highest estimated overall 12-month
prevalence (US, Ukraine, New Zealand), the mean num-
ber of days out of role associated with disorders classified
“severe” is in the range 98.1-142.5, compared to means in
the range 48.7-56.7 in the three countries with the lowest
12-month prevalence estimates (Nigeria, China, Japan).
Another possibility is that we under-estimated preva-
lence in some countries because the DSM categories are
less relevant to symptom expression in some countries
than others. We did not investigate this possibility in the
WMH surveys, but rather assumed that DSM categories
apply equally well to all countries. A sophisticated analy-
sis of the possibility that DSM categories might not apply
equally to all countries was carried out as part of the WHO
Collaborative Study on Psychological Problems in
General Health Care (PPG) (Üstün & Sartorius, 1995). In
that study, an analysis of cross-national variation in the
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structure of depressive symptom was carried out using
item response theory (IRT) methods (Simon et al., 2002).
The results showed clearly that both the latent structure of
depressive symptoms, and the associations between spe-
cific depressive symptoms and this latent structure, were
very similar across the countries studied. These results
argue against the suggestion that the large cross-national
variation in estimated prevalence of depression is due to
cross-national differences in the nature of depression.
Comparable psychometric analyses have not yet been
completed for other disorders, though, so it remains possi-
ble that cross-national differences exist in latent structure
that might play a part in explaining the substantial differ-
ences in 12-month prevalence documented in the WMH
surveys. New methodological studies are being carried out
by WMH collaborators to investigate this possibility.
At the same time, it is noteworthy that the countries with
the lowest disorder prevalence estimates in the WMH series
also have the highest proportions of treated cases classified
as “subthreshold;” that is, as not meeting criteria for any of
the DSM-IV/CIDI disorders assessed in the WMH inter-
view. This finding at least indirectly raises the possibility
that the assessments in the CIDI are less adequate in cap-
turing the psychopathological syndromes that are common
in all the WMH countries. In particular, the syndromes
associated with treatment in low-prevalence countries are
not well characterized by the CIDI. Additional WMH clin-
ical reappraisal studies using flexible and culturally sensi-
tive assessments of psychopathology are currently under-
way in both developed and developing countries aimed at
exploring the implications of this finding empirically.
LONG-TERM ADVERSE EFFECTS
OF MENTAL DISORDERS
Mental disorders are known to have much earlier ages-
of-onset (AOO) than most chronic physical disorders
(Kessler et al., 2007). The WMH survey results are con-
sistent with these previous findings. WMH respondents
with a lifetime history of each disorder were asked to
report retrospectively how old they were when the disor-
der first began. AOO distributions were generated from
these reports. Distributions are very consistent across
countries (Kessler et al., in press). Some anxiety disor-
ders, most notably the phobias and separation anxiety dis-
order (SAD), have very early AOO distributions, with
median AOO in the range 7-14 and the vast majority of
lifetime cases occurring with 5-10 years of these medians.
Similarly early onsets are typical for the externalizing dis-
orders considered in the WMH surveys. The other com-
mon anxiety disorders (panic disorder, generalized anxi-
ety disorder, and post-traumatic stress disorder) and mood
disorders, in comparison, have later AOO distributions,
with median AOO in the age range 25-50 and a wide IQR
(15-75). Substance use disorders, finally, have intermedi-
ate median AOO (20-35), with the vast majority of cases
having onsets within ten years of these medians.
WMH analyses show that early-onset mental disorders
are significant predictors of the subsequent onset and per-
sistence of a wide range of physical disorders (He et al.,
2008; Ormel et al., 2007). This is part of a larger pattern
of associations between early-onset mental disorders and
a wider array of adverse life course outcomes that might
be conceptualized as societal costs of these disorders,
including reduced educational attainment, early marriage,
marital instability, and low occupational and financial sta-
tus (Kessler et al., 1997; 1995; 1998). It is unclear if these
associations are causal; that is, if interventions to treat
early-onset mental disorders would prevent the subse-
quent onset of the adverse outcomes with which they are
associated. As a result, it is not possible to state unequiv-
ocally that these outcomes are consequences of mental
disorders. It would be very valuable from a public health
perspective to have long-term evidence to evaluate this
issue from experimental treatment effectiveness studies.
Even in the absence of this evidence, though, the available
data from the WMH surveys show that mental disorders,
and especially early-onset mental disorders, are associat-
ed with substantially reduce life changes in terms of phys-
ical health and achievements in a variety of role domains.
SHORT-TERM ADVERSE EFFECTS
OF MENTAL DISORDERS
A considerable amount of research has been carried out
to quantify the magnitude of the short-term societal costs
of mental disorders in terms of healthcare expenditures,
impaired functioning, and reduced longevity, but most of
this work has been done in the US (Greenberg &
Birnbaum, 2005; Greenberg et al., 1999). The magnitude
of the cost estimates in these studies is staggering. For
example, Greenberg et al. (1999) estimated that the annu-
al total societal costs of anxiety disorders in the US over
the decade of the 1990s exceeded $42 billion. This esti-
mate excludes the indirect costs of early-onset anxiety dis-
orders through adverse life course outcomes described in
the previous section (e.g., the effects of child-adolescent
anxiety disorders in predicting low educational attainment
and consequent long-term effects on lower income) and
through increased risk of other disorders (e.g., anxiety dis-
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disorder) and focuses exclusively on such short-term
effects as healthcare expenditures and days out of role.
Although comparable studies of the societal costs of
mental disorders have been carried out in only a few other
countries, a recent study of the comparative impairments in
role functioning caused by mental disorders and commonly
occurring chronic physical disorders in the WMH surveys
documented that mental disorders have substantial adverse
effects on functioning in many countries around the world
(Ormel et al., in press). This analysis made use of the fact
that physical disorders were assessed in the WMH surveys
with a standard chronic disorders checklist. Respondents
with the ten most commonly reported such disorders were
asked to report the extent to which each such disorder inter-
fered with their ability to carry out their daily activities in
both productive roles (i.e., job, school, housework) and
social roles (i.e., social and personal life). The same ques-
tions about disorder-specific role impairments were also
asked of respondents with each of the mental disorders
assessed in the surveys, the ten most commonly occurring
of which were compared to the ten physical disorders.
Of the 100 logically possible pair-wise disorder-specif-
ic mental-physical comparisons, the proportion of impair-
ment ratings in the severe range were higher for the men-
tal than physical disorder in 76 comparisons in developed
and 84 comparisons in developing countries. (Table V)
Nearly all of these higher mental-than-physical impair-
ment ratings were statistically significant at the .05 level
and hold in within-person comparisons (i.e., comparing
the reported impairments associated with a particular men-
tal-physical disorder pair in the sub-sample of respondents
who had both disorders). Furthermore, a similar pattern
holds when treated physical disorders are compared with
all (i.e., treated or not) mental disorders to address the con-
cern that the more superficial assessment of physical than
mental disorders might have led to the inclusion of sub-
threshold cases of physical disorders with low disability.
These results involve individual-level effects. It is also
instructive to examine societal-level effects, by which we
mean effects that take into consideration not only how
seriously impairing disorders are but also how prevalent
they are. We are only beginning to do this in the cross-
national WMH data, but results of this sort have been
generated for the US WMH survey (Merikangas et al.,
2007). That analysis estimated that fully one-third of all
the days out of role associated with chronic-recurrent
health problems in the US population are due to mental
disorders. This amounts to literally billions of days of lost
functioning per year in the US population. We do not yet
know if comparable results will be obtained in parallel
analyses of WMH surveys in other countries, but prelim-
inary results suggest that this might be the case.
THE COST-EFFECTIVENESS
OF TREATMENT INTERVENTONS
WMH analyses have been carried out to estimate the
magnitude of the effects of specific disorders on role func-
tioning in workplace settings (de Graaf et al., in press;
Kessler et al., 2006). The results are striking. In the US
WMH survey, for example, 6.4% of workers were found
to have an episode of major depressive disorder (MDD) in
the year of the survey, resulting in an average of over five
weeks of lost work productivity (Kessler et al., 2006).
Given the salaries of these workers, the annualized human
capital loss to employers in the US labor force associated
with MDD was estimated to be in excess of $36 Billion.
A similar result was found in a WMH analysis that esti-
mated the workplace costs of adult ADHD in ten WMH
surveys (de Graaf et al., in press). ADHD was found to be
associated with an average of 22 days excess lost produc-
tivity per worker with this disorder across the ten WMH
countries that assessed this disorder. Workplace costs as
large as these raise the question whether expansion of
detection, treatment, and treatment quality improvement
initiatives might be able to reduce the adverse workplace
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Table V – Disorder-specific global Sheehan Disability Scale ratings for
commonly occurring mental and chronicphysical disorders in developed
and developing WMH countries.
Proportion rated severely disabling
Developed Developing
Mean (se) Mean (se)
I. Physical disorders
Arthritis 23.3 (1.5) 22.8 (3.0)
Asthma 8.2* (1.4) 26.9 (5.4)
Back/neck 34.6* (1.5) 22.7 (1.8)
Cancer 16.6 (3.2) 23.9 (10.3)
Chronic pain 40.9* (3.6) 24.8 (3.8)
Diabetes 13.6 (3.4) 23.7 (6.1)
Headaches 42.1* (1.9) 28.1 (2.1)
Heart disease 26.5 (3.9) 27.8 (5.2)
High blood pressure 5.3* (0.9) 23.8 (2.6)
Ulcer 15.3 (3.9) 18.3 (3.6)
II. Mental disorders
ADHD 37.6 (3.6) 24.3 (7.4)
Bipolar 68.3* (2.6) 52.1 (4.9)
Depression 65.8* (1.6) 52.0 (1.8)
GAD 56.3* (1.9) 42.0 (4.2)
IED 36.3 (2.8) 27.8 (3.6)
ODD 34.2 (6.0) 41.3 (10.3)
Panic disorder 48.4* (2.6) 38.8 (4.7)
PTSD 54.8* (2.8) 41.2 (7.3)
Social phobia 35.1 (1.4) 41.4 (3.6)
Specific phobia 18.6 (1.1) 16.2 (1.6)
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effects of mental disorders to an extent that makes treat-
ment cost-effective from an employer perspective. An
effectiveness trial carried out in conjunction with the
WMH survey in the US evaluated this question experi-
mentally (Wang et al., 2007b). A large sample of workers
was screened for MDD and randomized to either a model
outreach and best-practices treatment intervention or to
usual care. The intervention group was found at six and
twelve months to have significantly higher job retention
than controls as well as significantly more hours worked
than controls (equivalent to an annualized two weeks
more work). The financial benefits of these intervention
effects (in terms of hiring and training costs, disability
payment, and salaries paid for sickness absence days)
were substantially higher than the costs of treatment, doc-
umenting that an expansion of workplace screening,
detection, and treatment of worker mental disorders can
be a human capital investment opportunity for employers.
Replications of this intervention experiment are currently
underway in other WMH countries, including Australia
and Japan. Extensions of the intervention to consider
treatment of bipolar depression and adult ADHD are also
underway. Ongoing analyses of the WMH data are also
being used to search for other intervention targets that can
be used to evaluate the effects of treatment in reducing the
burdens associated with mental disorders.
CONCLUSIONS
The data reviewed in this paper document that mental
disorders are commonly occurring in the general popula-
tion, often have an early age-of-onset, and often are asso-
ciated with significant adverse societal costs. We also
reviewed evidence to suggest that the current diagnostic
criteria might under-estimate the true prevalence of clini-
cally significant mental disorders, in which case the soci-
etal burdens of these disorders would be even greater than
estimated here. We also presented evidence to show that
some of these burdens can be reversed with best-practices
treatment. The latter finding argues much more persua-
sively than the naturalistic survey findings that mental dis-
orders are actual causes rather than merely correlates of
impaired role functioning. Based on these results, we can
safely conclude that mental disorders are common and
consequential from a societal perspective throughout the
world. Yet, as reported elsewhere, the WMH data show
that only a small minority of people with even seriously
impairing mental disorders receive treatment in most
countries and that even fewer receive high-quality treat-
ment (Wang et al., 2007a). This situation has to change. A
good argument could be made based on the WMH results
that an expansion of treatment would be a human capital
investment opportunity from the employer perspective.
The same argument could be made more generally to gov-
ernment policy-makers about human capital conse-
quences of expanded treatment from a societal perspec-
tive. Ongoing WMH analyses will continue to refine the
naturalistic analyses of the adverse effects of mental dis-
orders in an effort to target experimental interventions that
can demonstrate the value of expanded treatment to
address the enormous global burden of mental disorders.
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